Genmab A/S is a Danish biotechnology company, founded in February 1999 by BankInvest Biomedical venture fund lead by Florian Schönharting.Genmab is based in Copenhagen. Internationally, it operates through the subsidiaries Genmab BV in Utrecht, The Netherlands, and Genmab, Inc in Princeton, New Jersey, USA. The Company is publicly traded on the NASDAQ OMX Copenhagen A/S. Wikipedia.
van de Winkel J.G.J.,Genmab
Immunology Letters | Year: 2010
Insight into the biological role of antibody (Fc) receptors on immune and endothelial cells increased profoundly over the last decades. Fc receptors have been found to be crucial for normal immunity and to play an important role in the mechanisms of action of antibody therapeutics. This knowledge is key in designing and optimizing novel therapeutic strategies for human disease. © 2009 Elsevier B.V. All rights reserved.
Genmab | Date: 2014-12-10
The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.
Genmab | Date: 2015-08-19
Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins
Genmab | Date: 2014-03-06
The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein
Genmab | Date: 2014-06-27
Isolated monoclonal antibodies which bind to human CD32b and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.